3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
237
Lymphoma
176
Lymphoma, Large B-Cell, Diffuse
171
Precursor Cell Lymphoblastic Leukemia-Lymphoma
85
Lymphoma, Follicular
77
Lymphoma, Non-Hodgkin
72
Burkitt Lymphoma
66
Multiple Myeloma
62
Leukemia
58
Hodgkin Disease
45
Lymphoma, Mantle-Cell
41
Neoplasms
35
Lymphoma, T-Cell, Peripheral
31
Lymphoma, B-Cell
30
Lymphoma, B-Cell, Marginal Zone
27
Lymphoma, Large-Cell, Anaplastic
26
Lymphoma, Large-Cell, Immunoblastic
24
Neoplasm Metastasis
23
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Neoplasms, Plasma Cell
21
Recurrence
19
Immunoblastic Lymphadenopathy
15
Dendritic Cell Sarcoma, Interdigitating
15
Lymphoma, T-Cell
14
Leukemia, Biphenotypic, Acute
10
Waldenstrom Macroglobulinemia
9
Blast Crisis
9
Primary Myelofibrosis
8
Myelodysplastic Syndromes
8
Interventions
Mycophenolic Acid
2
vedolizumab
1
bavituximab
1
Ursodeoxycholic Acid
1
Steroids
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis
×
Prednisone
×
Clear all
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled